期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

顺铂分别联合培美曲塞和多西他赛治疗晚期肺腺癌的临床观察与分析 被引量：3

下载PDF
导出
摘要 目的比较晚期肺腺癌应用培美曲塞(PEM)+顺铂(DDP)和多西他赛(DOC)+顺铂(DDP)的临床效果。方法将54例晚期肺腺癌患者随机分成2组,治疗组(PEM+DDP)27例,对照组(DOC+DDP)27例,观察2组疗效及不良反应。结果治疗组总有效率48.1%,对照组总有效率44.4%。结论 DDP联合PEM或DOC治疗晚期肺腺癌均有较好的效果,疗效相似,PEM与DOC比较,PEM毒性反应较低,耐受性较好,是晚期肺腺癌患者适合的化疗方案。
作者 栾丽伟 赵智辅 金鑫 张杰
机构地区 黑龙江省鸡西市人民医院
出处 《中国医药指南》 2012年第5期188-189,共2页 Guide of China Medicine
关键词 肺腺癌 培美曲塞 多西他赛 顺铂 疗效
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献2

二级参考文献58

  • 1Zcllos L, Christiani DC. Epidemiology,biologic behavior, and natural history of mcsothclioma[ J]. Thorac Surg Clin,2004, 14:469-477. 被引量：1
  • 2Verschraegen C. Mesothelioma: Incidence and survival rates in the United States[ J]. Proc Am Soc Clin Oncol,2003 ,22 :869. 被引量：1
  • 3Robinson BW, Musk AW, Lake RA. Malignant mcsothclioma [ J]. Lancet,2005,366:397-408. 被引量：1
  • 4Weill H, Hughes JM, Churg AM. Changing trends in US mesothclioma incidence [ J]. Occup Environ Med, 2004,61 : 438- 441. 被引量：1
  • 5Manegold C. Coordinating author for the ESMO Guidelines Working Group. Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment, and follow-up [ J ]. Ann Oncol,2007,18 : ii34-ii35. 被引量：1
  • 6Flores RM, Krug LM,Rosenzweig KE, et al, Induction chemotherapy, extrapleural pneumonectomy, and postoperative highdose radiotherapy for locally advanced malignant pleural mesothelioma:A phase II trial[ J]. J Thorac Oncol,2006,1:289- 295. 被引量：1
  • 7Hazarika M,White RM,Johnson JR,et al. FDA drug approval summaries: pemetrexed (alimta) [ J ]. Oncologist, 2004,9 : 482- 488. 被引量：1
  • 8Zhao R,Babani S,Gao F,et al. The mechanism of transport of the multitargeted antifolate MTA-LY231514, and its cross-resistance pattern in cell with impaired transport of methotrexed [ J]. Clin Cancer Res,2000,6:3687-3695. 被引量：1
  • 9Miles DW, Smith IE, Coleman RE, et al. A phase II study of pemetrexed disodium( LY231514 )in patients with locally recurrent or metastatic breast cancer[ J]. Eur J Cancer,2001,37 : 1366-1371. 被引量：1
  • 10Spielmann M, Martin M, Namer M, et al. Activity of pemetrcxed( ALIMTA, multitargeted antifolate, LY231514 ) in metastatic breast cancer patients previously treated with an anthracycline and a taxane: an interim analysis [ J ]. Clin Breast Cancer,2001,2:47-51. 被引量：1

共引文献22

同被引文献34

  • 1Arriagada R,Bergman B,Dunant A,et al.Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer[J].N Engl J Med,2004,350:351-360. 被引量：1
  • 2Scagliotti GV,Parikh P,Von Pawel J,et al.Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus PMD etrexed in chemotherapy-naive patients with advanced-stage non-small cell lung cancer[J].J Clin Oncol,2008,26(21):3543-3551. 被引量：1
  • 3Manegold C,Schmid-Bindert G,Pilz LR.Pemetrexed for the treatment of non-small-cell lung cancer[J].Drug Profile,2009,9(9):1195-1209. 被引量：1
  • 4Laskin JJ,Nicholas G,Lee C,et al.Phase Ⅰ/Ⅱ trial of custirsen (OGX-011),an inhibitor of clusterin,in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non small cell lung cancer[J].J Thorac Oncol,2012,7(3):579-586. 被引量：1
  • 5Li L,Schaid DJ,Fridley BL,et al.Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer[J].Pharmacogenet Genomics,2012,22 (2):105-116. 被引量：1
  • 6Scagliotti G,Hanna N,Fossella F,et al.The differential efficacy of Pemetrexed according to NSCLC histology:a review of two phase Ⅲ studies[J].Oncologist,2009,14(3):253-263. 被引量：1
  • 7Syrigos KN,Vansteenkiste J,Parikh P,et al.Prognostic and predictive factors in a randomized phase Ⅲ trial comparing cisplatin pemtrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer[J].Ann Oncol,2010,21 (3):556-561. 被引量：1
  • 8Ciuleanu TE,Brodowiez T,Belani CP,et al.Maintenance Pemetrexed plus best supportive care(BSC) versu splacebo plus BSC:a phase Ⅲstudy[J].J Clin Oncol,2008,26(15 Supp 1):8011. 被引量：1
  • 9Peng G,Zinner RG,Wang Y,et al.Comparison of patient outcomes stratified by histology among Pemetrexed(P)-treated patients(pts) with stage Ⅲb/Ⅳ non-small cell lung cancer (NSCLC) in two phase Ⅰ trials[J].J Clin Oncol,2008,26 (15Supp 1):809. 被引量：1
  • 10Giorgiol V,Purvish P,Joachim VP,et al.Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer[J].J Clin Neol,2008,26 (21):3543-3551. 被引量：1

引证文献3

二级引证文献21

中国医药指南
2012年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部